We are live on ! Find out more
DMAA

Drugs Made In America Acquisition Corp
DMAA

24 hedge funds and large institutions have $171M invested in Drugs Made In America Acquisition Corp in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

58.79% more ownership

Funds ownership: 0% → 58.79% (+59%)

Holders
24
Holders Change
+24
Holders Change %
–
% of All Funds
0.32%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KIM
Karpus Investment Management
New York
+$23.2M
2
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$22.1M
3
FTCM
First Trust Capital Management
Illinois
+$20.7M
4
PAMP
Polar Asset Management Partners
Ontario, Canada
+$19M
5
GCL
Glazer Capital LLC
New York
+$18.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
KIM
1
Karpus Investment Management
New York
$23.3M +$23.2M +2,324,034 New
FTCM
2
First Trust Capital Management
Illinois
$20.7M +$20.7M +2,066,702 New
PAMP
3
Polar Asset Management Partners
Ontario, Canada
$19M +$19M +1,900,000 New
GCL
4
Glazer Capital LLC
New York
$18.3M +$18.2M +1,822,952 New
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$18M +$18M +1,800,000 New
WCMNY
6
Westchester Capital Management (New York)
New York
$9.81M +$9.79M +979,000 New
AC
7
Aristeia Capital
Connecticut
$9.02M +$9M +900,000 New
QL
8
Quarry LP
New York
$6.51M +$6.5M +650,000 New
WAM
9
Wolverine Asset Management
Illinois
$6.04M +$6.03M +603,038 New
ASM
10
ATW SPAC Management
New York
$5.71M +$5.7M +570,000 New
MSU
11
Mizuho Securities USA
New York
$5.4M +$5.43M +542,962 New
LP
12
LMR Partners
United Kingdom
$5.01M +$5M +500,000 New
WA
13
Whitebox Advisors
Minnesota
$4.01M +$4M +400,000 New
AA
14
AQR Arbitrage
Connecticut
$3.81M +$3.8M +380,314 New
DAM
15
DLD Asset Management
New York
$3.51M +$3.5M +350,000 New
MP
16
Mangrove Partners
Connecticut
$3.51M +$3.5M +350,000 New
Toronto Dominion Bank
17
Toronto Dominion Bank
Ontario, Canada
$3.47M +$22.1M +2,210,100 New
SSA
18
Schonfeld Strategic Advisors
New York
$2M +$2M +200,000 New
CA
19
Crossingbridge Advisors
New York
$1.3M +$8.5M +850,000 New
Goldman Sachs
20
Goldman Sachs
New York
$1.2M +$1.2M +119,686 New
WAM
21
Warberg Asset Management
Illinois
$922K +$920K +92,055 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$456K +$455K +45,462 New
VF
23
Virtu Financial
New York
$318K +$318K +31,777 New
Morgan Stanley
24
Morgan Stanley
New York
$200 +$200 +20 New

DMAA Hedge Fund Activity: Q1 2025 in Review

24 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp (DMAA) for Q1 2025, worth a combined $171M.

Buyers outnumbered sellers: 24 funds opened new DMAA positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Karpus Investment Management, opening a new position worth an estimated $23.2M.

  • 24 institutional investors held Drugs Made In America Acquisition Corp (DMAA) as of Q1 2025, up from 0 in Q4 2024.
  • Funds reported $171M of Drugs Made In America Acquisition Corp stock for Q1 2025.
  • 24 funds opened new Drugs Made In America Acquisition Corp positions in Q1 2025 and 0 closed out, a net change of +24 holders.
  • The largest Drugs Made In America Acquisition Corp buyer in Q1 2025 was Karpus Investment Management, an estimated $23.2M added.

Based on aggregated 13F filings for Q1 2025.